Detects  mutations in key genes recurrently mutated in acute myeloid leukemia (AML). DNA sequence of targeted regions of the ASXL1, BCOR, CEBPA, CSF3R, DNMT3A, EZH2, IDH1, IDH2, KIT, KRAS, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2 genes is determined using next-generation sequencing (NGS) technology.

Available as an add-on in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers include cCD3, cCD22, CD33, CD34, CD45, CD79a, cMPO and nTdT.